Taken together, it can be suggested that inhibition of SGLT2 increases energy consumption by increasing intra-adipose sympathetic innervation to counter diet-induced obesity and reveals a new therapeutic strategy by which SGLT2 inhibitors positively regulate energy homeostasis [52]. Here, SLC5A2 is linked to obesity disorder.